We are live on ! Find out more
KYTX icon

Kyverna Therapeutics

99 hedge funds and large institutions have $321M invested in Kyverna Therapeutics in 2025 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 9

135% more capital invested

Capital invested by funds: $136M → $321M (+$184M)

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

38% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 21

32% more funds holding

Funds holding: 7599 (+24)

25.45% more ownership

Funds ownership: 52.48%77.93% (+25%)

19% less call options, than puts

Call options by funds: $967K | Put options by funds: $1.19M

Holders
99
Holders Change
+24
Holders Change %
+32%
% of All Funds
1.2%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
36
Increased
29
Reduced
21
Closed
9
Calls
$967K
Puts
$1.19M
Net Calls
-$227K
Net Calls Change
-$1.29M
Name Holding Trade Value Shares
Change
Change in
Stake
EC
76
EntryPoint Capital
New York
$94.5K +$74.6K +10,048 New
CAI
77
Capital Advisors Inc
Oklahoma
$94K
CUAMC
78
China Universal Asset Management Company
China
$67.1K -$3.29K -443 -6%
Fidelity Investments
79
Fidelity Investments
Massachusetts
$65.6K -$6.99K -942 -12%
TRCT
80
Tower Research Capital (TRC)
New York
$47.7K -$8.6K -1,158 -19%
JP Morgan Chase
81
JP Morgan Chase
New York
$40.2K -$17.8K -2,401 -36%
Deutsche Bank
82
Deutsche Bank
Germany
$36.8K
Osaic Holdings
83
Osaic Holdings
Arizona
$30.3K +$5.38K +725 +29%
Royal Bank of Canada
84
Royal Bank of Canada
Ontario, Canada
$30K +$9.23K +1,243 +62%
Mirae Asset Global Investments
85
Mirae Asset Global Investments
South Korea
$20K +$3.38K +456 +27%
PNC Financial Services Group
86
PNC Financial Services Group
Pennsylvania
$15.7K
Russell Investments Group
87
Russell Investments Group
United Kingdom
$12.3K
VWWMG
88
Vermillion & White Wealth Management Group
Pennsylvania
$10.3K +$8.17K +1,100 New
GFM
89
GF Fund Management
China
$8.08K -$282 -38 -4%
National Bank of Canada
90
National Bank of Canada
Quebec, Canada
$3.76K +$2.97K +400 New
Nisa Investment Advisors
91
Nisa Investment Advisors
Missouri
$2.83K
TFM
92
TFC Financial Management
Massachusetts
$2.82K +$2.23K +300 New
FDW
93
Fourth Dimension Wealth
Ohio
$2.35K
Carson Wealth (CWM LLC)
94
Carson Wealth (CWM LLC)
Nebraska
$2K -$1.75K -236 -47%
EWA
95
EverSource Wealth Advisors
Alabama
$1.53K -$275 -37 -19%
Jones Financial Companies
96
Jones Financial Companies
Missouri
$348 +$275 +37 New
PA
97
Parallel Advisors
California
$244 +$193 +26 New
SS
98
SBI Securities
Japan
$207 -$854 -115 -84%
AAP
99
Arax Advisory Partners
Colorado
$103
Franklin Resources
100
Franklin Resources
California
-$4.07M -677,587 Closed

KYTX Hedge Fund Activity: Q4 2025 in Review

99 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q4 2025, worth a combined $321M — up 135% from $136M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new KYTX positions and 9 closed out — a net gain of 27 holders — while 29 added to existing stakes and 21 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $14.8M. The largest seller was Franklin Resources, exiting entirely with an estimated $4.07M sold.

  • 99 institutional investors held Kyverna Therapeutics (KYTX) as of Q4 2025, up from 75 in Q3 2025.
  • Funds reported $321M of Kyverna Therapeutics stock for Q4 2025, up 135% quarter-over-quarter.
  • 36 funds opened new Kyverna Therapeutics positions in Q4 2025 and 9 closed out, a net change of +27 holders.
  • The largest Kyverna Therapeutics buyer in Q4 2025 was Deerfield Management, an estimated $14.8M added.
  • The largest Kyverna Therapeutics seller in Q4 2025 was Franklin Resources, an estimated $4.07M sold.

Based on aggregated 13F filings for Q4 2025.